<p>Stevanato Group S.p.A. has announced a collaboration with Datwyler and LTS Device Technologies to expand self-delivery options for large-volume drugs. This partnership aims to enable more convenient on-body delivery of high-dose therapies, such as anti-cancer treatments and monoclonal antibodies, by utilizing a pre-verified large-volume platform solution. The joint effort features Datwyler’s NeoFlex™ plungers for larger volume containers, Stevanato Group’s ready-to-use EZ-fill® cartridges, and LTS Device Technologies’ Sorrel™ Platform, which is capable of delivering from 10 and 20mL cartridges. The collaboration is designed to accelerate time to market and support the shift from hospital to home administration of sensitive therapies. Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Stevanato Group S.p.A. published the original content used to generate this news brief via PR Newswire (Ref. ID: EN64697) on January 16, 2026, and is solely responsible for the information contained therein. © Copyright 2026 - Public Technologies (PUBT)</p>

Stevanato Group Partners with Datwyler and LTS Device Technologies to Expand Self-Delivery Drug Solutions